GenScript Make Research Easy

Rev07 Update: Apr,11,2024

#### DATASHEET

# LR<sup>3</sup>-IGF-I (Receptor Grade), Human


Cat. No.: Z03177

#### **Product Introduction**


| Species                   | Human   |
|---------------------------|---|
| Protein Construction      | Expressed with additional N-terminal sequence (MFPAMPLSSLFVNGPRT).  |
|                           | LR3-IGF-I (Leu53-Ala118)<br>Accession # P05019  |
| Purity                    | > 95% as analyzed by SDS-PAGE   |
| Endotoxin Level           | < 1 EU/µg of protein by gel clotting method   |
| Biological Activity       | $ED_{50}$ < 10.0 ng/ml, measured by the dose-dependant<br>proliferation of CHO cells, corresponding to a specific activity of > 1.0<br>$\times$ 10^5 units/mg.  |
| Expression System         | E. coli   |
| Apparent Molecular Weight | ~9.1 KDa, on SDS-PAGE under reducing conditions.  |
| Formulation               | Lyophilized after extensive dialysis against 50 mM acetic acid.   |
| Reconstitution            | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in 10 mM HCl up to 1mg/ml   |
| Storage & Stability       | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upor reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at 20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
|                           |   |

### Examples





 $ED_{50} < 10.0$  ng/ml, measured by the dose dependent proliferation of CHO cells, corresponding to a specific activity of > 1.0 × 10<sup>5</sup> units/mg.



Lane 1: 2 μg of LR3-IGF-I (Receptor Grade), Human, nonreducing (NR) Lane 2: 2 μg of LR3-IGF-I (Receptor Grade), Human, reducing (R) > 95% as analyzed by SDS-PAGE

#### Background

**Target Background :** IGF-1 is a well-characterized basic peptide secreted by the liver that circulates in the blood. It has growth-regulating, insulin-like, mitogenic activities. IGF-1 is a growth factor that has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to IGF-2, which is also a major fetal growth factor. Human Long R3 Insulin-like Growth Factor-1 (rhLR3IGF-1) contains an 83 amino acid analog of human IGF-I. Compared to the complete human IGF-I sequence, an addition of the rhLR3IGF-1 includes the substitution of an Arg for the Glu at position 3 (hence R3) and a13 amino acid extension peptide at the N-terminus. An enhanced potency is due to the markedly decreased binding of human Long-R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs.

Synonyms: LR3 Insulin-like Growth Factor-I; LR3-IGF-I

## For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

生产商:南京金斯瑞生物科技有限公司 江苏省南京市江宁区科学园雍熙路28号 Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28 Yongxi Road, Jiangning District, Nanjing, Jiangsu, China